NUMERO: #20250180

Título: HYPOSALIVATION AND ORAL MANIFESTATIONS IN A PATIENT WITH MULTIPLE MYELOMA UNDERGOING TALQUETAMAB THERAPY: A CASE SERIES

Nome do Apresentador: Christian Ferreira BERNARDI

Categoria do Trabalho: Painel de caso clínico (PCC)

Área Temática: Odontologia hospitalar

Resumo: Talquetamab is a novel bispecific antibody targeting GPRC5D, recently approved for patients with relapsed or refractory multiple myeloma. While systemic adverse events are well documented, oral toxicities remain underreported. We describe three cases of heavily pretreated multiple myeloma patients undergoing Talquetamab therapy who developed xerostomia and/or dysgeusia. In the first case, two unstimulated sialometry tests showed a salivary flow rate of 0.06 mL/min, consistent with severe hyposalivation. The second patient reported dysgeusia, with sialometry results of 0.2 mL/min, 0.1 mL/min, and 0.5 mL/min-below normal values. In the third case, flow rates were 0.06 mL/min, 0.2 mL/min, and 0.7 mL/min, indicating hyposalivation with partial improvement. These oral adverse effects may result from off-target Talquetamab activity in GPRC5D-expressing salivary gland tissues or immune-mediated glandular dysfunction. These cases highlight the need to monitor oral toxicities during Talquetamab treatment.

Autor 1:  Christian Ferreira BERNARDI

E-mail 1:  [email protected]

Autor 2:   Patrick Polcaro de Paiva SANTOS

E-mail 2:  [email protected]

Autor 3 :  Luiza Deitos MENTI

E-mail 3:  [email protected]

Autor 4:  Juliana Mota SIQUEIRA

E-mail 4:  [email protected]

Autor 5:  Anna Luíza Damaceno ARAÚJO

E-mail 5:  [email protected]

Autor 6:  Fernanda de Paula EDUARDO

E-mail 6:  [email protected]

Autor 7:  Mariana Henriques FERREIRA

E-mail 7:  [email protected]